745 related articles for article (PubMed ID: 9694607)
1. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.
Frasci G; Comella P; D'Aiuto G; Budillon A; Barbarulo D; Thomas R; Capasso I; Casaretti R; Daponte A; Caponigro F; Gravina A; Maiorino L; Caratení G; Gentile A; Comella G
Breast Cancer Res Treat; 1998 May; 49(1):13-26. PubMed ID: 9694607
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
[TBL] [Abstract][Full Text] [Related]
3. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study.
Frasci G; D'Aiuto G; Comella P; Thomas R; Capasso I; Di Bonito M; Rivellini F; Carteni G; De Lucia L; Maiorino L; D'Aniello R; Frezza P; Lapenta L; Comella G
Breast Cancer Res Treat; 2000 Jul; 62(2):87-97. PubMed ID: 11016746
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
6. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.
Livingston RB; Ellis GK; Gralow JR; Williams MA; White R; McGuirt C; Adamkiewicz BB; Long CA
J Clin Oncol; 1997 Apr; 15(4):1395-400. PubMed ID: 9193331
[TBL] [Abstract][Full Text] [Related]
7. Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin-treated patients.
Ellis GK; Gralow JR; Pierce HI; Williams MA; Livingston RB
J Clin Oncol; 1999 May; 17(5):1407-12. PubMed ID: 10334525
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-paclitaxel weekly schedule in advanced solid tumors: a phase I study.
Frasci G; Comella P; Parziale A; Casaretti R; Daponte A; Gravina A; De Rosa L; Gallipoli A; Comella G
Ann Oncol; 1997 Mar; 8(3):291-3. PubMed ID: 9137800
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
Schwartsmann G; Mans DR; Menke CH; Xavier N; Caleffi M; Ferreira Filho AF; Schunemann H; Kalakun L; Koya R; Pohlman P; Venegas LF
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):24-9. PubMed ID: 9144687
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity.
Wasserheit C; Frazein A; Oratz R; Sorich J; Downey A; Hochster H; Chachoua A; Wernz J; Zeleniuch-Jacquotte A; Blum R; Speyer J
J Clin Oncol; 1996 Jul; 14(7):1993-9. PubMed ID: 8683229
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer.
Fisherman JS; Cowan KH; Noone M; Denicoff A; Berg S; Poplack D; Balis F; Venzon D; McCabe M; Goldspiel B; Chow C; Ognibene FP; O'Shaughnessy J
J Clin Oncol; 1996 Mar; 14(3):774-82. PubMed ID: 8622023
[TBL] [Abstract][Full Text] [Related]
13. Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer.
Pagani O; Sessa C; Martinelli G; Cerny T; de Jong J; Goldhirsch A; Zimatore M; Cavalli F
Ann Oncol; 1997 Jul; 8(7):655-61. PubMed ID: 9296218
[TBL] [Abstract][Full Text] [Related]
14. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
Vassilomanolakis M; Koumakis G; Demiri M; Missitzis J; Barbounis V; Efremidis AP
Cancer Invest; 2003; 21(4):497-504. PubMed ID: 14533438
[TBL] [Abstract][Full Text] [Related]
15. Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.
Holmes FA
Semin Oncol; 1995 Aug; 22(4 Suppl 8):9-15. PubMed ID: 7543702
[TBL] [Abstract][Full Text] [Related]
16. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
17. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
Klaassen U; Wilke H; Seeber S
J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
[TBL] [Abstract][Full Text] [Related]
18. Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients.
Frasci G; D'Aiuto G; Thomas R; Comella P; Di Bonito M; Lapenta L; D'Aiuto M; Botti G; Vallone P; De Rosa V; D'Aniello R; Giordano R; Comella G
Oncology; 2005; 68(4-6):391-7. PubMed ID: 16020968
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.
Frasci G; Panza N; Comella P; Cartení G; Guida T; Nicolella GP; Natale M; Lombardi R; Apicella A; Pacilio C; Gravina A; Lapenta L; Comella G
Ann Oncol; 1999 Mar; 10(3):355-8. PubMed ID: 10355583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
